Phase II Clinical Trials

• CT236 · PDF 表观遗传免疫重编程克服转移性黑色素瘤患者的PD-1耐药：II期NIBIT-ML1研究 Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: The phase II NIBIT-ML1 study Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Francesca Pia Caruso, Maura Colucci, Vincenzo D'Alonzo, Raffaella Grifoni, Roberta Depenni, Laura Solmonese, Francesco Marzani, Emma Bello, Antonio De Falco, Monica Valente, Ramiz Rana, Elena Carbonari, Giovanni Amato, Elena Manenti, Ilenia Vizzari, Sandra Coral, Harold Keer, Aram Oganesian, Danna Chan, Roberta Mortarini, Maresa Altomonte, Diana Giannarelli, Andrea Anichini, Teresa Noviello, Michele Ceccarelli, Michele Maio
• CT237 · PDF SCOPE：一项在一线晚期黑色素瘤中联合检查点阻断的现成DNA质粒疫苗II期临床试验，显示出良好的T细胞应答，且与长期无进展生存相关 SCOPE, A phase 2 clinical trial with off-the-shelf DNA plasmid vaccine in first line advanced melanoma combined with check point blockade, shows good T cell responses which correlate with long progression free survival Joseph Chadwick, Samantha Paston, Kate Young, Heather Shaw, Pippa Corrie, Sarah Danson, Miranda Payne, Poulam Patel, Maria Marples, Ioannis Karydis, Satish Kumar, Clare Barlow, Rebecca Lee, Martin Highley, Kellati Prasad, Georgia Goodhew, Olivia Howard, Joe Thornton, Nermeen Varawalla, Lindy Durrant
• CT238 · PDF 瘤内注射sotigalimab联合pembrolizumab可快速激活抗原呈递细胞，并在转移性黑色素瘤未注射肿瘤中驱动抗肿瘤应答：一项I/II期研究 Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, Emre Arslan, Reham Abdel-Wahab, Sung-Nam Cho, Xiaodong Yang, Daniel H Johnson, Rodabe N Amaria, Isabella C Glitza, Patrick Hwu, Hussein A Tawbi, Jared K Burks, Michael A Davies, Kunal Rai, Suhendan Ekmekcioglu, Adi Diab
• CT240 · PDF IOB-032/PN-E40：一项新辅助/辅助IO102-IO103癌症疫苗联合pembrolizumab治疗可切除HNSCC的2期研究 IOB-032/PN-E40: A phase 2 study of neoadjuvant/adjuvant IO102-IO103 cancer vaccine plus pembrolizumab in resectable HNSCC Barbara Burtness, Ravindra Uppaluri, Michael J. Dennis, Annette M. Lim, Richard A. Scolyer, Erin Alesi, Ayako Wakatsuki Pedersen, Amy Wesa, Ravi K. Adapala, Ulla Kring Hansen, Marcos Iglesias, Bushi Wang, Cecilie Abildgaard, Qasim Ahmad, Francois Ringeisen, Georgina V. Long, Robert I. Haddad
• CT241 · PDF 乙胺嘧啶治疗局部区域晚期头颈部鳞状细胞癌的2期机会窗口试验 Phase 2 window of opportunity trial of pyrimethamine in locoregionally advanced head and neck squamous cell carcinoma Paul Zolkind, Emily M. Wilkerson, Harit Panda, Julius Chembo, James Sun, Kate Zhao, Jessica Ley, Michael Atteberry, Nathan Wamsley, Sidra Major, Kynlee Giesie, Luke Chen, Ryan S. Jackson, Jason Rich, Patrik Pipkorn, Alex Harbison, Anthony J. Apicelli, Jennifer De Los Santos, Wade L. Thorstad, Sidharth V. Puram, Peter Oppelt, Douglas Adkins, Michael B. Major
• CT242 · PDF 共价FAPI成像引导的甲状腺髓样癌精准手术 Covalent FAPI imaging-guided precision surgery in medullary thyroid carcinoma Ziren Kong, Yang Liu, Yan-Song Lin, Zhu Li, Xi-Yang Cui, Shengyan Liu, Xin Zhang, Ruochen Li, Ye Yang, Yuning Sun, Yongdu Nie, Zongmin Zhang, Changming An, Song Ni, Yiming Zhu, Zhibo Liu, Jian Wang, Shaoyan Liu
• CT243 · PDF Dirozalkib治疗晚期ALK阳性非小细胞肺癌（NSCLC）患者：一项2期研究的结果 Dirozalkib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC): Results from a phase 2 study Ying Liu, Yan Yu, Zhiye Zhang, Ruiling Ning, Yulan Sun, Meili Sun, Dairong Li, Li Wang, Xianghui Duan, Xuejie Guo, Yan Hu, Weili Liu, Haifeng Liu
• CT244 · PDF Taletrectinib治疗酪氨酸激酶抑制剂（TKI）经治的ROS1+非小细胞肺癌（NSCLC）患者：TRUST-I和TRUST-II的更新数据 Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II Geoffrey Liu, Jorge Nieva, Lyudmila Bazhenova, Chang-Min Choi, Qitao Yu, Shunichi Sugawara, Noriko Yanagitani, Filippo de Braud, Huijie Fan, Enriqueta Felip, Emilio Bria, Maurice Pérol, Feiwu Ran, Wei Wang, Xianyu Zhang, Michael Chen, Caicun Zhou
• CT245 · PDF PDR001治疗携带KRAS/NRAS突变或无可靶向遗传学异常的不可切除非小细胞肺癌（NSCLC）患者：II期、多中心、单臂研究 PDR001 in patients with unresectable non-small cell lung cancer (NSCLC) harboring KRAS/NRAS mutation or without actionable genetic abnormalities: Phase II, multicenter, single arm study Yeong Hak Bang, Seong-Eun Kim, Shinkyo Yoon, Dae Ho Lee, Bhumsuk Keam, Dong-Wan Kim, Sang-We Kim
• CT246 · PDF PEOPLE II期试验（NCT03447678）中用于PD-L1低表达/阴性疾病NSCLC患者化疗降级的集成多组学框架 An ensemble multi-omics framework for chemo de-escaltion NSCLC patients with PD-L1-low/negative disease in the PEOPLE phase II trial (NCT03447678) Luca Mauro Invernizzi, Ghazal Farhikhteh, Arianna Rigamonti, Sabrina Pervin Abu, Donato Cosi, Cecilia Silvestri, Luca Agnelli, Tiziana Triulzi, Marta Brambilla, Michela Francesconi, Francesco Sgambelluri, Mario Occhipinti, Maria Chiara Garassino, Roberta Mortarini, Filippo De Braud, Claudia Proto, Francesco Trovò, Monica Ganzinelli, Giuseppe Lo Russo, Arsela Prelaj
• CT247 · PDF Savolitinib联合Durvalumab治疗伴MET改变的EGFR野生型晚期NSCLC患者（SOUND）：一项多中心、开放标签的II期临床试验 Savolitinib combined with Durvalumab in EGFR wild-type advanced NSCLC patients with MET alterations (SOUND): A multicenter, open-label, Phase II trial Yong-Feng Yu, Xiao-Ying Huang, Qian Chu, An-Wen Liu, Li Zhuang, Xiao-Rong Dong, Hong-Cheng Wu, Jian-Ying Zhou, Shun-Dong Cang, Yan Wang, Yi Hu, Zhen-Zhou Yang, Meng-di Wu, Xiao-yuan Wang, Shun Lu
• CT248 · PDF Zidesamtinib治疗既往接受过repotrectinib或taletrectinib治疗的ROS1+NSCLC患者 Zidesamtinib in patients with ROS1 + NSCLC previously treated with repotrectinib or taletrectinib Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, Adrianus Johannes de Langen, Alice T. Shaw, Jonathan W. Riess, Marina Garassino, Elaine Shum, Christina S. Baik, Jessica R. Bauman, D. Ross Camidge, Chien-Chung Lin, Gee-Chen Chang, Dong-Wan Kim, Myung-Ju Ahn, Ji-Youn Han, Kiichiro Ninomiya, Ryo Ariyasu, Ross Andrew Soo, Sanjay Popat, Jürgen Wolf, Maria Rosario García Campelo, Vivek A. Upadhyay, Stephen V. Liu
• CT249 · PDF 在支气管灌洗液中检测EGFR T790M突变及lazertinib在一线EGFR-TKI失败后T790M阳性NSCLC患者中的疗效：一项开放标签、多中心、单臂探索性研究 Detection of EGFR T790M mutation in bronchial washing fluid and therapeutic efficacy of lazertinib in T790M-positive NSCLC patients after first-line EGFR-TKI failure: An open-label, multicenter, single-arm exploratory study Chi Young Kim, Se Hyun Kwak, Eun Hye Lee, Sang Hoon Lee, Eun Young Kim, Yoon Soo Chang
• CT250 · PDF JK06（一种靶向5T4的抗体药物偶联物）治疗不可切除的局部晚期或转移性癌症患者的1b/2期研究 A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer Omar Saavedra, Fabricio Racca, Valentina Boni, Emiliano Calvo, Brant Delafontaine, Sylvie Rottey, Bernd Dekeyser, Hans Prenen, Maria deMiguel, Valentina Gambardella, Lionel d'Hondt, Vladimir Galvao, Judit W. Johnson, Jonathan P. McNally, Jennifer Lindelien, Alice Drumheller, Jijun Dong, Samuel P. Murphy, Shalabh Singhal, Naimish Pandya, Nuria Kotecki
• CT252 · PDF 双肺移植治疗转移性局限于肺部的非小细胞肺癌（NSCLC）患者：一个病例系列 Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series Young Kwang Chae, Liam Il-Young Chung, Ronald Seungjune S. Min, Sanghwa Kim, Ben Ponvilawan, Chan Mi Jung, Yuchan Kim, Brooke Sanson, Rose Dwyer, Tarik Demir, Chitaru Kurihara, Ambalavanan Arunachalam, Ankit Bharat
• CT253 CT253 印度首例，一项针对复发或难治性多发性骨髓瘤的本土化改良、经济高效的自体双靶点BCMA/CD19 CAR T细胞疗法的1/2期研究 First in India, phase 1/2 study of an indigenously adapted, cost-efficient autologous dual-target BCMA/CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma Uday Kumar Surampudi, Prashant Kashinath Bhavar, Partha Pratim Sarma, Rishi Rahangdale, Guoxiang WU
• CT254 · PDF 二甲双胍预防前驱多发性骨髓瘤进展的随机安慰剂对照2期研究结果 Results of a randomized placebo-controlled phase 2 study of metformin for the prevention of progression of precursor multiple myeloma Catherine R. Marinac, Robert Redd, Adam S. Sperling, Lorenzo Trippa, Victoria A. Kelly, Shonali Midha, Elizabeth K. O'Donnell, Paul G. Richardson, Irene M. Ghobrial, Omar Nadeem
• CT255 · PDF BETA-PRIME试验中的AdAPT-001：空间和时间上协调的TGF-beta抑制与溶瘤感染 AdAPT-001 in the BETA-PRIME trial: Spatially and temporally coordinated TGF-beta inhibition and oncolytic infection Chris Larson, Vinod Ravi, Jeannie Williams, Erica Burbano, Meaghan Stirn, Scott Caroen, Bryan Oronsky, Anthony P. Conley, Tony Reid
• CT256 · PDF 一项针对晚期血管肉瘤的化疗/免疫治疗II期研究：采用节拍式吉西他滨、多柔比星、多西他赛联合nivolumab（NCT04535713）——中期分析 A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis Samantha Jeffrey, Piya Mann, Oliver Davidorf, Anmol Dia Agarwal, Sarah Lande, Mihir Chawla, Neal Chawla, Ania Moradkhani, Ted Kim, Victoria Chua-Alcala, Sant Chawla, Erlinda Gordon
• CT257 · PDF 近期有恶性肿瘤病史患者的双肺移植 Double lung transplantation in patients with recent history of malignancy Young Kwang Chae, Liam IL-Young Chung, Ronald Min, Sanghwa Kim, Ben Ponvilawan, Chan Mi Jung, Yuchan Kim, Brooke Sanson, Rose Dwyer, Carolyn Moloney, Tarik Demir, Chitaru Kurihara, Ambalavanan Arunachalam, Ankit Bharat
• CT258 · PDF 从癌症幸存者视角看数字化生存期照护规划：一项I/II期随机对照试验的定性分析 Digital survivorship care planning through the eyes of cancer survivors: A qualitative analysis of a phase I/II randomized controlled trial Shalet James, Maria S. Rangwala, Amber S. Kleckner
• CT259 · PDF 罕见肿瘤中联合抗肿瘤药物的快速分析与缓解评估（RARE CANCER）试验（RARE 3）：Tiragolumab + Atezolizumab Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial (RARE 3): Tiragolumab + Atezolizumab Amanda Walker, Naoko Takebe, Murielle Hogu, Sarah J. Shin, Jared Foster, Andre De Souza, Lamin Juwara, Katherine V. Ferry-Galow, Ralph E. Parchment, Laura Kuhlmann, Helen X. Chen, James H. Doroshow, Alice P. Chen, Jibran Ahmed
• CT260 · PDF Pembrolizumab联合azacitidine的表观遗传修饰可重编程铂耐药上皮性卵巢癌的肿瘤微环境：一项II期研究的临床与转化研究结果 Pembrolizumab and epigenetic modification with azacitidine reprogram the tumor microenvironment of platinum-resistant epithelial ovarian cancer: clinical and translational findings from a phase II study Blair V. Landon, Julia L. Boland, Andrea E. Wahner Hendrickson, Deborah K. Armstrong, Boris Winterhoff, Jaime Wehr, Akshaya V. Annapragada, Christopher Cherry, Archana Balan, Guneet Kaleka, Victor E. Velculescu, Stephen B. Baylin, Cynthia A. Zahnow, Dennis J. Slamon, Gottfried E. Konecny, John A. Glaspy, Valsamo (Elsa) Anagnostou
• CT261 · PDF 分子碘可削弱乳腺癌治疗中的化疗耐药性及不良反应 Molecular iodine impairs chemotherapy resistance and adverse effects in breast cancer treatments Jorge V. Gil Leyva, Bruno Estrada-Jimenez, Jessica Vega-Mera, Ximena Ramirez-Morales, Alejandro Ruiz-Diego, Evangelina Delgado-Gonzalez, Guillermo Peralta, Brenda Anguiano, Carmen Aceves
• CT262 · PDF Elacestrant（Ela）联合everolimus（Eve）或abemaciclib（Abema）用于ER+/HER2-局部晚期或转移性乳腺癌（mBC）患者：ELEVATE（一项开放标签伞式研究）的2期结果 Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi, Marina N. Sharifi, Wassim McHayleh, Thaddeus Beck, Neelima Vidula, Erika Hamilton, Kristine J. Rinn, Joyce O’Shaughnessy, Giuseppe Curigliano, Javier Cortés, Paula Muñoz Romero, Giulia Tonini, Alessandro Paoli, Monica Binaschi, Li Cheng, Jennifer A. Crozier, Tomer Wasserman, Virginia Kaklamani
• CT263 · PDF 术前低剂量azacitidine在高危早期乳腺癌中的机会窗试验 Window of opportunity trial of preoperative low dose azacitidine in high-risk early-stage breast cancer Maria Jose Godoy Calderon, Abhigna Kodali, Manali Patwardhan, Saanvi Sethi, Meredith Russell, Eric Gauchat, Michelle Karan, Zhengjia Chen, Oana Danciu, Kent Hoskins, Abiola Ibraheem, VK Gadi

在会议检索中浏览本分会场